Table 6.
Main Ongoing Trials of PARPi Combined with ICIs
| Trial | Cancer Type | Line of Treatment | PARP Inhibitor | Immunotherapy | Phase |
|---|---|---|---|---|---|
| UNITO–001 | HRR-positive and PD-L1 ≥ 1% advanced NSCLC and/or MPM | ≥2 | Niraparib | TSR-042 (anti-PD-1 mAb) | II |
| NCT03307785 | Advanced or metastatic cancer | ≥1 | Niraparib | TSR-042 (anti-PD-1 mAb) | I |
| NCT02484404 | Advanced or metastatic cancer | N line | Olaparib | Durvalumab | I/II |
| NCT03559049 | Non-squamous NSCLC | Maintenance | Rucaparib | Pembrolizumab | I/II |
| NCT03308942 | NSCLC | 1/2 | Niraparib | Pembrolizumab/TSR-042 (anti-PD-1 mAb) | II |
| NCT03330405 | NSCLC, TNBC, HR+ breast cancer, ovarian cancer, UC, CRPC. | ≥1 | Talazoparib | Avelumab | II |
| NCT03334617 (HUDSON) | NSCLC | ≥2 | Olaparib | Durvalumab | II |
| NCT03775486 (ORION) | NSCLC | Maintenance | Olaparib | Durvalumab Compared to: Durvalumab | II |
| NCT03976323 (KEYLYNK-006) | Non-squamous NSCLC | Maintenance | Olaparib | Pembrolizumab Compared to: Pembrolizumab + chemotherapy | III |
| NCT03976362 (KEYLYNK-008) | Squamous NSCLC | Maintenance | Olaparib | Pembrolizumab Compared to: Pembrolizumab + chemotherapy + placebo | III |
| NCT04380636 (KEYLYNK −012) | NSCLC | Maintenance | Olaparib | Pembrolizumab Compared to: Pembrolizumab + placebo Compared to: Durvalumab | III |
| NCT04173507 Lung-MAP | Non-squamous STK11-positive NSCLC | ≥2 | Talazoparib | Avelumab | II |
Abbreviations: TNBC, triple-negative breast cancer; HR+, hormone receptor-positive; UC, urothelial cancer; CRPC, castration-resistant prostate cancer.